Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Several molecularly targeted drugs for treating radioiodine resistant differentiated thyroid carcinomas (RAIR-DTC) have been identified. Among these, lenvatinib has been approved for clinical use in many countries (1).
Lenvatinib is approved by both the FDA and the EMA for the treatment of differentiated thyroid cancer (DTC) that is radioiodine-refractory, meaning it no longer responds to radioactive iodine therapy (2, 3)
The clinical phase II treatment trial, identified as NCT02657369, demonstrated that the safety profile of lenvatini…